Polymer-Drug Conjugates as Nanotheranostic Agents

Tutkimustuotos: LehtiartikkeliKatsausartikkelivertaisarvioitu

154 Lataukset (Pure)


Since the last decade, the polymer-drug conjugate (PDC) approach has emerged as one of the most promising drug-delivery technologies owing to several benefits like circumventing premature drug release, offering controlled and targeted drug delivery, improving the stability, safety, and kinetics of conjugated drugs, and so forth. In recent years, PDC technology has advanced with the objective to further enhance the treatment outcomes by integrating nanotechnology and multifunctional characteristics into these systems. One such development is the ability of PDCs to act as theranostic agents, permitting simultaneous diagnosis and treatment options. Theranostic nanocarriers offer the opportunity to track the distribution of PDCs within the body and help to localize the diseased site. This characteristic is of particular interest, especially among those therapeutic approaches where external stimuli are supposed to be applied for abrupt drug release at the target site for localized delivery to avoid systemic side effects (e.g., Visudyne®). Thus, with the help of this review article, we are presenting the most recent updates in the domain of PDCs as nanotheranostic agents. Different methodologies utilized to design PDCs along with imaging characteristics and their applicability in a wide range of diseases, have been summarized in this article.
JulkaisuJournal of Nanotheranostics
DOI - pysyväislinkit
TilaJulkaistu - 13 maalisk. 2021
OKM-julkaisutyyppiA2 Arvio tiedejulkaisuussa (artikkeli)


Sukella tutkimusaiheisiin 'Polymer-Drug Conjugates as Nanotheranostic Agents'. Ne muodostavat yhdessä ainutlaatuisen sormenjäljen.